Understanding chronic rejection after lung transplantation
Advancing our Understanding of the Development, Phenotypes, and Progression of Chronic Rejection after Lung Transplantation
This study is looking at why some lung transplant patients experience ongoing rejection of their new lungs, and it aims to create tools that help doctors predict who might be at risk, so they can provide better, personalized care to improve patients' lives and chances of survival.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11005004 on NIH RePORTER |
What this research studies
This research investigates the causes and progression of chronic rejection, known as chronic lung allograft dysfunction (CLAD), in lung transplant recipients. It aims to develop clinical risk prediction models that combine patient-specific clinical data with biological signals found in bronchoalveolar lavage fluid. By identifying risk factors and understanding the interplay of immune responses and lung microbiota, the research seeks to improve personalized care for lung transplant patients. The ultimate goal is to enhance survival rates and quality of life for those affected by CLAD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone lung transplantation and are at risk for chronic rejection.
Not a fit: Patients who have not received a lung transplant or those with acute rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction and management of chronic rejection in lung transplant patients, improving their long-term outcomes.
How similar studies have performed: Previous studies have shown promise in identifying biological signals related to CLAD, indicating that this research builds on existing knowledge in the field.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Combs, Michael Peter — University of Michigan at Ann Arbor
- Study coordinator: Combs, Michael Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.